Clinical Trials ArenaOriginal article
Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint
Phase 2positiveafimetoranPositive
AI Analysis
Summary
Beeline Medicines announced that its Phase II clinical trial of afimetoran in adults with active moderate-to-severe systemic lupus erythematosus achieved its primary endpoint. This positive Phase II result advances the program toward potential later-stage development.
Clinical Trial Data
Phase
Phase II
Primary Endpoint
Met
Outcome Details
Primary endpoint met in global Phase II trial in adults with active moderate-to-severe SLE
Importance:7/10
Sentiment:
0.80
Phase IIclinical trialprimary endpointSLEafimetoran
Read the original article
Published by Clinical Trials Arena on September 10, 2026 9:45 AM